SURPASS-2

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagonlike peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.

In patients with type 2 diabetes who were receiving metformin, the novel once-weekly dual glucose-dependent insulinotropic polypeptide– GLP-1 receptor agonist tirzepatide was noninferior and superior to the selective GLP-1 receptor agonist semaglutide (at a dose of 1 mg) with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks.